Clinical Trial Update: ASP-II: Ancrod Stroke Program: Ancrod (Viprinex™) for the Treatment of Acute, Ischemic Stroke [Phase 3]

View source ↗

Summary

Phase 3 trial ASP-II for Ancrod (Viprinex) in acute ischemic stroke has been terminated; no results are presented in this update.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Stroke

Drugs mentioned

• Viprinex (ancrod)

Snippet

Sponsor: Neurobiological Technologies | Conditions: Stroke, Cerebral Ischemia | Phase 3 | Status: TERMINATED